KemPharm to Present at Upcoming Investor Conferences
Tweet
Share
E-mailGet Alerts KMPH Hot Sheet
Join SI Premium – FREE
Management Presentations to Focus on Depth of Product Pipeline
CORALVILLE, Iowa, Feb. 07, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that President and Chief Executive Officer, Travis Mickle, Ph.D., will present at the following five investor conferences during February and March.
Details of KemPharm's presentations are as follows:
| Event: | BIO CEO & Investor Conference | |
| Date: | Tuesday, February 14, 2017 | |
| Time: | 11:30 a.m. (ET) | |
| Location: | The Waldorf Astoria, New York, NY |
| Event: | RBC Capital Markets 2017 Global Healthcare Conference | |
| Date: | Wednesday, February 22, 2017 | |
| Time: | 9:00 a.m. (ET) | |
| Location: | The New York Palace Hotel, New York, NY |
| Event: | Cowen & Co. 36th Annual Health Care Conference 2017 | |
| Date: | Tuesday, March 7, 2017 | |
| Time: | 8:00 a.m. (ET) | |
| Location: | The Boston Marriott Copley Place, Boston, MA |
| Event: | 29th Annual ROTH Conference | |
| Date: | Conference Date March 12-15, 2017 | |
| Time: | Presentation date/time to be scheduled | |
| Location: | The Ritz Carlton, Dana Point, CA |
| Event: | Oppenheimer & Co. 27th Annual Healthcare Conference | |
| Date: | Tuesday, March 21, 2017 | |
| Time: | 9:45 a.m. (ET) | |
| Location: | The Westin New York Grand Central, New York, NY |
All presentation webcasts will available on the Investor Relations section of the KemPharm website at http://investors.kempharm.com/ following delivery at the respective conferences.
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system disorders. KemPharm’s co-lead clinical development candidates are KP415, an extended-release prodrug of methylphenidate for the treatment of ADHD, and KP201/IR, an acetaminophen-free formulation of the company’s immediate release abuse deterrent hydrocodone product candidate, KP201. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com.
Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 [email protected] [email protected] Media Contact: Daniel L. Cohen Executive VP, Government and Public Relations KemPharm, Inc. 202-329-1825 [email protected]Source: KemPharm
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- argenx SE (ARGX) PT Raised to $1,100 at RBC Capital, 'We Think Approval In DM Is When, Not If'
- Meals on Wheels America, Caesars Entertainment and The Just One Project Partner in Local Hunger Relief Initiative
- AXIL Brands, Inc. Reports Fiscal 2026 and Fourth Quarter Financial Results
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
RBC Capital, Cowen & Co, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
